Thermopylae Holdings Ltd. 4
4 · AbCellera Biologics Inc. · Filed Mar 2, 2026
Research Summary
AI-generated summary of this filing
AbCellera (ABCL) 10% Owner Thermopylae Buys 38,000 Shares
What Happened
- Thermopylae Holdings Ltd., listed as a 10% owner of AbCellera Biologics, acquired 38,000 common shares on February 27, 2026. The weighted-average price reported was $3.44 per share, for a total reported value of $130,720. The transaction is coded "P" (purchase) and was an open-market or private purchase.
Key Details
- Transaction date: 2026-02-27; Filing date (Form 4): 2026-03-02 (timely filed).
- Price: weighted-average $3.44; underlying trade prices ranged $3.42–$3.45 (per footnote).
- Total reported value: $130,720.
- Shares owned after transaction: not specified in the provided filing excerpt.
- Footnote: the $3.44 figure is a weighted-average; Thermopylae offers to provide a breakdown of how many shares were bought at each price within the $3.42–$3.45 range upon request.
Context
- This was a straightforward purchase by a 10% institutional owner, not an executive insider trade. Purchases can be more informative than sales, but this filing alone doesn’t explain intent. No option exercises, awards, gifts, or tax-withholding events were reported in the provided details.
Insider Transaction Report
Form 4
Thermopylae Holdings Ltd.
10% Owner
Transactions
- Purchase
Common Shares
[F1]2026-02-27$3.44/sh+38,000$130,720→ 56,134,097 total
Footnotes (1)
- [F1]The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $3.42 to $3.45. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.
Signature
Tryn Stimart, attorney-in-fact|2026-03-02